TABLE 2.
Factors associated with a positive SARS-CoV-2 rapid diagnostic test (RDT)a
| Univariate analysis |
Multivariate analysis |
|||||
|---|---|---|---|---|---|---|
| Variables | OR | 95% CI | P value | OR | 95% CI | P value |
| SARS-CoV-2 Delta variant | 2.54 | 1.35–4.88 | 0.004 | 1.09 | 0.09–12.36 | 0.943 |
| Female sex | 1.22 | 0.62–2.36 | 0.556 | - | - | - |
| Time between onset of symptoms and clinical sampling | 0.86 | 0.71–1.04 | 0.127 | 0.88 | 0.58–1.27 | 0.504 |
| Time between onset of symptoms and last vaccine injection | 1.01 | 0.99–1.01 | 0.066 | - | - | - |
| No. of symptoms | 1.34 | 1.02–1.79 | 0.042 | 0.69 | 0.19–2.16 | 0.544 |
| Rhinitis | 0.77 | 0.36–1.61 | 0.485 | - | - | - |
| Fever | 2.20 | 1.01–5.10 | 0.055 | 1.18 | 0.09–17.76 | 0.898 |
| Dry cough | 1.95 | 0.91–4.33 | 0.092 | 5.59 | 0.62–78.24 | 0.146 |
| Headache | 0.73 | 0.33–1.63 | 0.443 | - | - | - |
| Sore throat | 0.63 | 0.25–1.63 | 0.337 | - | - | - |
| Asthenia | 1.02 | 0.42–2.63 | 0.959 | - | - | - |
| Anosmia | 2.99 | 0.46–58.14 | 0.325 | - | - | - |
| Ageusia | - | - | - | - | - | - |
| Myalgia | 3.17 | 1.26–9.15 | 0.020 | 5.87 | 0.58–109.4 | 0.166 |
| SARS-CoV-2 E gene (Ct) | 0.44 | 0.31–0.56 | <0.0001 | 0.34 | 0.14–0.55 | 0.001 |
| SARS-CoV-2 RIs (Ct) | 0.47 | 0.36–0.59 | <0.0001 | - | - | - |
aCI, confidence interval; Ct, cycle threshold; E gene, SARS-CoV-2 envelope glycoprotein gene; OR, odds ratio; RI, replicative intermediate RNAs; RNA, RNA; -, parameter not included in uni- or multivariate analysis.